熱門資訊> 正文
Immatics任命行业资深人士为首席财务官
2025-10-01 20:14
- Immatics N.V. (NASDAQ:IMTX) has appointed Venkat Ramanan as chief financial officer, effective immediately.
- Ramanan brings 25+ years of biopharma finance experience, with leadership roles at Seagen, Gilead (GILD), Amgen (AMGN), and most recently as CFO at Anthos Therapeutics, acquired by Novartis in April 2025.
- Ramanan succeeds Arnd Christ.
- Ramanan will help lead commercial preparations for Immatics’ lead PRAME-targeting cell therapy, anzu-cel, in metastatic melanoma.
- Source: Press release
More on Immatics
- Seeking Alpha’s Quant Rating on Immatics
- Historical earnings data for Immatics
- Financial information for Immatics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
